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Strategies to overcome the limited availability of human articular chondrocytes and
their tendency to dedifferentiate during expansion are required to advance their
clinical use and to engineer functional cartilage on par with native articular cartilage.
This work sought to determine whether a biochemical factor (transforming
growth factor‐β1 [T]), a biophysical agent (chondroitinase‐ABC [C]), and a collagen
crosslinking enzyme (lysyl oxidase‐like 2 [L]) are efficacious in forming three‐
dimensional human neocartilage from expanded human articular chondrocytes.
Among the treatment regimens, the combination of the three stimuli (TCL treatment)
led to the most robust glycosaminoglycan content, total collagen content, and type II
collagen production. In particular, TCL treatment synergistically increased tensile
stiffness and strength of human neocartilage by 3.5‐fold and 3‐fold, respectively, over
controls. Applied to two additional donors, the beneficial effects of TCL treatment
appear to be donor independent; tensile stiffness and strength were increased by
up to 8.5‐fold and 3‐fold, respectively, over controls. The maturation of human
neocartilage in response to TCL treatment was examined following 5 and 8 weeks
of culture, demonstrating maintenance or further enhancement of functional proper-
ties. The present study identifies a novel strategy for engineering human articular
cartilage using serially passaged chondrocytes.
KEYWORDS
cartilage tissue engineering, chondrocyte expansion, chondroitinase‐ABC, human articular
chondrocytes, lysyl oxidase‐like 2, neocartilage maturation1 | INTRODUCTION
Current surgical treatments to repair cartilage lesions involve
microfracture, chondroplasty, osteochondral autograft/allograft (e.g.,
mosaicplasty), and autologous chondrocyte implantation (Huang, Hu,
& Athanasiou, 2016; McCormick et al., 2014; Montgomery et al.,
2014). However, formation of fibrocartilaginous tissue, inadequate
integration with adjacent host tissue, donor site morbidity, lesion size
restrictions, and poor long‐term outcomes signify the need for further
improvement of techniques for effective cartilage repair (Makris,
Gomoll, Malizos, Hu, & Athanasiou, 2015; Richter, Schenck, Wascher,wileyonlinelibrary.co& Treme, 2016). As a promising early disease‐modifying treatment for
cartilage degeneration, tissue engineering aims to replace cartilage
lesions with in vitro‐generated neocartilage possessing functional
properties akin to native tissue (Huey, Hu, & Athanasiou, 2012).
Human articular chondrocytes (hACs) as an autologous cell source
are used for cell‐based and tissue‐engineered cartilage products for
clinical use in knee cartilage defect (Huang et al., 2016). Chondrocyte
expansion in monolayer is known to dedifferentiate cells, elevating
type I collagen expression and diminishing chondrogenic potential
(Cournil‐Henrionnet et al., 2008; Schulze‐Tanzil, 2009; von der Mark,
Gauss, von der Mark, & Muller, 1977). As a result, tissue‐engineered© 2018 John Wiley & Sons, Ltd.m/journal/term 283
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Previously, an effective regimen by a combined treatment of
transforming growth factor‐β1 (TGF‐β1), growth differentiation
factor‐5 (GDF‐5), and bone morphogenetic protein‐2 (BMP‐2) during
postexpansion in aggregate culture has been shown to revert hACs
into a chondrogenic phenotype with reproduced type II collagen and
glycosaminoglycan (GAG)‐rich matrix (Murphy, Huey, Hu, &
Athanasiou, 2015). Scaffold‐free neocartilage constructs derived from
the redifferentiated hACs generated robust cartilaginous tissue,
though functional properties of the resulting neocartilage were insuf-
ficient and significantly lower when compared with the properties of
native tissue.
To improve the functionality of engineered cartilage, various
exogenous stimuli including signalling molecules and matrix‐
modifying agents have been investigated (Kwon, Paschos, Hu, &
Athanasiou, 2016). Particularly, direct modification of the engineered
tissues with a biophysical agent (chondroitinase‐ABC [c‐ABC]) and a
collagen crosslinking enzyme (lysyl oxidase‐like 2 [LOXL2]), in
modulating biochemical content and enhancing collagen crosslinks,
respectively, has led to improvements in the mechanical properties
of engineered cartilage (Makris, Responte, Paschos, Hu, &
Athanasiou, 2014; Natoli, Responte, Lu, & Athanasiou, 2009; Natoli,
Revell, & Athanasiou, 2009). Temporal suppression of GAG in tissue‐
engineered cartilage by c‐ABC, an enzyme that degrades chondroitin
and dermatan sulfates (Prabhakar et al., 2006), has been shown to
significantly enhance collagen production and increase tensile
mechanical properties (Bian et al., 2009; Natoli, Responte, et al.,
2009; Natoli, Revell, et al., 2009). Interestingly, a combined treat-
ment of c‐ABC and TGF‐β1 synergistically increased collagen con-
tent in neocartilage and significantly improved tensile stiffness
when compared with application of each factor alone (Responte,
Arzi, Natoli, Hu, & Athanasiou, 2012). LOXL2 forms covalent
pyridinoline (PYR) crosslinks between collagen fibres, which play an
important role in controlling swelling properties of proteoglycan to
provide appropriate tensile and shear properties of cartilage
(Asanbaeva, Masuda, Thonar, Klisch, & Sah, 2007). Exogenous
LOXL2 has been shown to significantly improve tensile properties
of engineered musculoskeletal tissues, resulting in increased amount
of PYR crosslinking (Makris, Responte, et al., 2014). Applying
TGF‐β1, c‐ABC, and LOXL2 simultaneously to bovine
fibrocartilaginous tissues enhanced tensile properties by increasing
collagen density and fibril diameter (Makris, MacBarb, Paschos, Hu,
& Athanasiou, 2014), though it is still unclear if the combined effects
will likewise be seen for articular cartilage or for tissues generated
using human cells.
The application of exogenous stimuli and the resulting effect can
vary with different species and cell passage (Akens & Hurtig, 2005;
Guerne, Sublet, & Lotz, 1994). Interestingly, hACs isolated from
donors of different ages have been shown to reveal distinctive
responses to different growth factors (Guerne, Blanco, Kaelin,
Desgeorges, & Lotz, 1995). Outcome discrepancies resulting from dif-
ferences in species, passage number, and donor source motivate the
present work for translating regimens verified in animal cells to human
cells. Evaluating the responsiveness of human passaged cells from
multiple donors to the exogenous stimuli (TGF‐β1, c‐ABC, and LOXL2)not only will confirm the utility of developing regimens first using ani-
mal cells but also will lead to effective strategies for engineering func-
tional human cartilage tissue.
The scaffold‐free, self‐assembling process has been successful in
generating mechanically robust neocartilage (Athanasiou,
Eswaramoorthy, Hadidi, & Hu, 2013). Matrix development and
mechanical properties in self‐assembly of articular cartilage over
8 weeks of culture have been shown to recapitulate the developmen-
tal process of native articular cartilage (Ofek et al., 2008). In this prior
report, during the phase of neocartilage development (1–3 weeks), fol-
lowing cadherin‐mediated cell interactions, chondrocytes produced
immature matrices consisting primarily of type VI collagen and
chondroitin‐6‐sulfate (CS‐6). During the maturation phase at 4 weeks
of culture and beyond, the formed construct contained mature matri-
ces consisting primarily of type II collagen with pericellularly localized
type VI collagen and decreased level of CS‐6/CS‐4 ratio, mimicking
the developmental process of native tissue.
Given the remarkable role of LOXL2 and c‐ABC, together with
TGF‐β1, in generating neocartilage using animal cells (Makris,
MacBarb, et al., 2014; Makris, Responte, et al., 2014; Natoli, Revell,
et al., 2009), it is of interest to apply them towards engineering
human articular cartilage. The objectives of this study were (a) to
investigate the translatability of a biochemical factor, a biophysical
agent, and a collagen crosslinking enzyme, applied on expanded
hACs, on improving the biochemical and mechanical properties of
engineered human neocartilage; (b) to evaluate the robustness of
the response using different donors; and (c) to investigate
neocartilage maturation. In Study I, TGF‐β1, c‐ABC, and LOXL2 were
applied alone or in combination to test the hypothesis that efficacies
shown using animal cells are also applicable to human cells. Further-
more, it was hypothesized that a combined treatment of the three
stimuli results in the greatest enhancement of neocartilage func-
tional properties. In Study II, the most effective combination of stim-
uli from Study I was carried forward to test the hypothesis that the
influence of treatment on improving hAC neocartilage properties is
donor independent. Just as the stimuli were effective during the
developmental phase of the engineered neocartilage, it was also
hypothesized that the functional properties are further enhanced
during the maturation phase.2 | MATERIALS AND METHODS
2.1 | Isolation and expansion of chondrocytes
Human articular cartilage was obtained from the Musculoskeletal
Transplant Foundation (Kansas City, MO), a tissue bank. This research
is exempt from institutional review board approval because it does not
constitute as human subject research. The demographic information of
the donors are as follows: Donor 1: 43 years of age, male, and Cauca-
sian; Donor 2: 19 years of age, male, and Caucasian; and Donor 3:
21 years of age, male, and Caucasian. Cartilage was minced, washed
in washing medium composed of Dulbecco's modified Eagle's medium
with high glucose/GlutaMAX™ (Life Technologies, Grand Island, NY)
and 1% penicillin–streptomycin–fungizone (P/S/F; Lonza, Basel,
KWON ET AL. 285Switzerland), and followed by digestion in 0.2% collagenase type II
(Worthington, Lakewood, NJ) and 3% fetal bovine serum (Atlanta Bio-
logicals, Lawrenceville, GA) for 18 hr at 37°C in washing medium. Iso-
lated chondrocytes were passed through a 70‐μm strainer to remove
any undigested cartilage. The cells were counted and stored in liquid
nitrogen until use. hACs were expanded in chemically defined
chondrogenic culture medium (CHG; Dulbecco's modified Eagle's
medium with high glucose/GlutaMAX, 1% P/S/F, 1% nonessential
amino acids [Life Technologies], 1% ITS+ Premix [BD Biosciences],
50 μg/ml ascorbate‐2‐phosphate [Sigma‐Aldrich, St. Louis, MO],
40 μg/ml L‐proline [Sigma], 100 μg/ml sodium pyruvate [Sigma], and
100 nM dexamethasone [Sigma]), supplemented with 2% fetal bovine
serum, 1 ng/ml TGF‐β1 (PeproTech, Rocky Hills, NJ), 10 ng/ml
platelet‐derived growth factor (PeproTech), and 5 ng/ml basicFIGURE 1 Schematic diagram of the study. (a) Isolation and expansion of
expansion and aggregate culture before self‐assembly of neocartilage. (b) S
growth factor‐β1 (TGF‐β1), chondroitinase‐ABC (c‐ABC), and lysyl oxidase
determine the most effective regimen to improve functional properties. (c)
forward and applied to two additional donors to examine the robustness o
regimen. Ctrl: control [Colour figure can be viewed at wileyonlinelibrary.cofibroblast growth factor (PeproTech). Cells were passaged three times
using 0.05% Trypsin–EDTA (Life Technologies), followed by 0.2% col-
lagenase type II solution (Figure 1a).2.2 | Aggregate culture for postexpansion
chondrogenic differentiation
Passaged hACs were seeded on 1% agarose‐coated plates at a density
of 750,000 cells per ml and maintained in aggregate culture for 7 days
in CHG supplemented with 10 ng/ml TGF‐β1, 100 ng/ml GDF‐5, and
100 ng/ml BMP‐2. After 7 days of culture, aggregates were treated
with 0.05% Trypsin–EDTA and digested in 0.2% collagenase type IIhuman articular chondrocytes (hACs). hACs underwent chondrogenic
tudy I: Neocartilage derived from Donor 1 treated with transforming
‐like 2 (LOXL2), separately or in combination, was evaluated to
Study II: The most effective regimen selected from Study I was carried
f neocartilage and maturation using the TGF‐β1 + c‐ABC + LOXL2
m]
286 KWON ET AL.solution. Digested cells were filtered through a 70‐μm strainer and
used in neocartilage formation (hAC neocartilage) (Figure 1a).2.3 | Neocartilage self‐assembly and treatment
hAC neocartilage was formed through the self‐assembling process as
described previously (Hu & Athanasiou, 2006). Briefly, a custom stain-
less steel mould, structured with 5‐mm diameter cylindrical prongs,
was immersed in 2% agarose solution in a 48‐well plate and allowed
to solidify. Solidified agarose 5‐mm well plates were washed with
washing medium at least twice prior to cell seeding. A total of
2 × 106 hACs in 100 μl of CHG supplemented with 200 unit/ml hyal-
uronidase type I‐S from bovine testes (Sigma) and 2 μM cytochalasin
D (Enzo Life Sciences, Farmingdale, NY) were added to each well.
For treatment of TGF‐β1, c‐ABC, and LOXL2, self‐assembled
neocartilage was maintained in CHG supplemented with (a) 10 ng/ml
TGF‐β1, (b) 2 unit/ml c‐ABC, or (c) 0.15 μg/ml LOXL2. On the basis
of previously identified regimen of combined treatment of TGF‐β1,
c‐ABC, and LOXL2 (Makris, MacBarb, et al., 2014), in Study I,
neocartilage was treated with c‐ABC at Day 7, LOXL2 from Day 7
to Day 21, and TGF‐β1 throughout the culture period (Figure 1b).
The robustness of the response using different donors and
neocartilage maturation were examined in Study II using the regimen
determined in Study I (Figure 1c). At Day 7, c‐ABC was applied for
4 hr at 37°C, and 1 mM zinc sulfate was used to stop the reaction
for 10 min at 37°C. From Day 7 to Day 21, LOXL2 was added contin-
uously in CHG with 0.146 mg/ml hydroxylysine and 1.6 μg/ml copper
sulfate. CHG was added 4 hr after seeding and exchanged every 24 hr.
For the first 72 hr, 2 μM cytochalasin D was added in CHG. After
neocartilage was unconfined from the agarose well plate and trans-
ferred to an uncoated 24‐well plate, medium was exchanged every
other day.2.4 | Histological evaluation
Neocartilage constructs were fixed in 10% neutral‐buffered formalin
for histological evaluation. Samples were embedded in paraffin and
sectioned at a thickness of 5 μm. Sections were subsequently proc-
essed and stained with hematoxylin and eosin (H&E), Safranin O,
and Picrosirius Red using standard protocols. Immunohistochemistry
was used to detect type I and II collagen in samples. The type I and
II collagen expression was developed using Vectastain ABC and DAB
substrate kits.2.5 | Mechanical and biochemical evaluation
After 5 or 8 weeks of culture, hAC neocartilage was collected for
mechanical and biochemical assessment (n = 4–8 per donor). For
mechanical properties, compressive and tensile properties of
neocartilage were evaluated. Unconfined compressive testing was
performed using an Instron 5565. Samples were submerged in phos-
phate buffered saline and preconditioned by applying 15 cycles of
5% compressive strain followed by sequential stress‐relaxation tests
at 10% and 20%. The standard linear solid model was used todetermine instantaneous modulus (Ei), relaxation modulus (Er), and
coefficient of viscosity (μ; Mow, Kuei, Lai, & Armstrong, 1980). Tensile
testing was performed using a TestResources 840L. Samples were
tested at a constant strain rate of 1% per second. Young's modulus
(EY) and ultimate tensile strength (UTS) were analysed using a custom
MATLAB program.
For biochemical evaluation, the GAG and total collagen content in
each sample was assessed. Weights of samples were measured before
and after samples were frozen and lyophilized. Samples were digested
in 125 μg/ml papain (Sigma) in phosphate buffer for 18 hr at 60°C.
GAG content was measured using a Blyscan Glycosaminoglycan Assay
kit (Biocolor, Newtownabbey, Northern Ireland). Total collagen con-
tent was measured using a chloramine‐T hydroxyproline assay and
SIRCOL collagen standard (Accurate Chemical and Scientific Corp.,
Westbury, NY).2.6 | Statistical analysis
All data are presented as mean ± standard deviation. The statistical
differences of mechanical properties and biochemical contents among
conditions were analysed in a one‐way analysis of variance with
Tukey's post hoc test using the JMP v12 statistical software package.
Groups with different letters indicate that there are statistically signif-
icant differences (p < 0.05).3 | RESULTS
3.1 | Study I
3.1.1 | Gross morphology and histology of hAC
neocartilage
In Study I, hAC neocartilage was subjected to exogenous stimuli
TGF‐β1, c‐ABC, and LOXL2 alone or in combination to investigate
their effects on improving the functional properties. Gross morpholog-
ical images of self‐assembled neocartilage are shown in Figure 2a. In
general, neocartilage thickness increased when treated with TGF‐β1
compared with groups without TGF‐β1. The surface also appeared
uneven following treatment with TGF‐β1 or with TGF‐β1 + c‐ABC
(TC) and appeared curved following treatment with TGF‐β1 + LOXL2
(TL). Neocartilage treated with all three stimuli (TGF‐β1 + c‐
ABC + LOXL2 or TCL) was flatter and more opaque than all other
groups, possibly due to increased matrix deposition.
For histological evaluation, hAC neocartilage was assessed using
H&E, Safranin O, and Picrosirius Red staining (Figures 2b and S1).
Cross‐sectional images of the entire neocartilage in all conditions are
shown in Figure S2. Neocartilage in all conditions displayed
chondrocytes in lacunae, as demonstrated by H&E staining (Figure
S3). In the native cartilage, pericellular matrix exhibited more intense
staining. Due to the high cell density, the pericellular matrix in
neocartilage is not as easily discerned. Although all neocartilage
stained positively for Safranin O, considerably more intense staining
was observed in TGF‐β1‐treated groups (Figure 2b). Similarly,
Picrosirius Red staining was observed in all neocartilages, and the
FIGURE 2 Gross morphology and histology of self‐assembled human neocartilage at 5 weeks. (a) Top and side views of human neocartilage
derived from Donor 1. (b) Hematoxylin and eosin (H&E) and Safranin O (Saf‐O) staining of human neocartilage derived from Donor 1. Ctrl:
control; C: chondroitinase‐ABC; L: lysyl oxidase‐like 2; CL: chondroitinase‐ABC + lysyl oxidase‐like 2; T: transforming growth factor‐β1; TC:
transforming growth factor‐β1 + chondroitinase‐ABC; TL: transforming growth factor‐β1 + lysyl oxidase‐like 2; TCL: transforming growth
factor‐β1 + chondroitinase‐ABC + lysyl oxidase‐like 2 [Colour figure can be viewed at wileyonlinelibrary.com]
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S1). Type I collagen expression was not detected in either control or
TCL‐treated neocartilage (Figure 6a). Type II collagen expression was
richer in TCL‐treated neocartilage when compared with control
(Figure 6b).3.1.2 | Biochemical and mechanical properties of
hAC neocartilage
The amount of GAG and total collagen content of hAC neocartilage at
5 weeks was evaluated per wet weight (Figure 3). Treating the
neocartilage with c‐ABC alone did not significantly affect GAG con-
tent (Figure 3a). The GAG content in c‐ABC‐treated neocartilage
was significantly increased by 25% when combined with TGF‐β1.
hAC neocartilage treated with LOXL2 alone or a combination of
LOXL2 and c‐ABC (CL) contained significantly lower GAG content
compared with control. This effect was countered by TGF‐β1 addition;
TCL treatment increased GAG content by 75% compared with CL
treatment (Figure 3a) and by 52% compared with control. All treat-
ments, with the exception of c‐ABC treatment alone, significantly
increased collagen content when compared with control (Figure 3b).
In addition, TGF‐β1 treatment significantly enhanced the effect of
LOXL2 as well as c‐ABC with respect to collagen content. Among
the treatment regimens, TL and TCL treatments resulted in signifi-
cantly larger collagen contents, exhibiting 71% increases over control.The mechanical properties of engineered hAC neocartilage were
assessed in both compression and tension (Figure 3). hAC neocartilage
treated withTCL exhibited the highest average instantaneous modulus
of 331 kPa, which represents an 87% increase over control (Figure 3c).
The relaxation modulus in hAC neocartilage, treated with each factor
either alone or in combination, was not significantly different when
compared with that of control (Figure 3d). Tensile stiffness was signif-
icantly increased with TL and TCL treatment by 230% and 350%,
respectively, when compared with control (Figure 3e). These increases
were greater than the sum of the effects of each factor applied alone,
indicating synergistic effects of the combined treatment. LOXL2 treat-
ment significantly increased UTS compared with control (Figure 3f).
TGF‐β1, c‐ABC, or TC treatment did not enhance tensile strength.
TCL treatment had the largest effect on the tensile strength, resulting
in 0.8 ± 0.1 MPa. There was also synergism on the effects of TL and
TCL, which increased tensile strength by 150% and 300%, respec-
tively, over control.3.2 | Study II
3.2.1 | The robustness of TCL treatment in forming
hAC neocartilage examined using different donors
The TCL treatment was carried forward to Study II, and hAC
neocartilage derived from two additional donors was evaluated for
FIGURE 3 Biochemical and mechanical properties of self‐assembled human neocartilage at 5 weeks. (a) Glycosaminoglycan (GAG) content in
human neocartilage derived from Donor 1 normalized by wet weight (WW). (b) Total collagen (COL) content in human neocartilage derived
from Donor 1 normalized by WW. (c) Instantaneous modulus and (d) relaxation modulus were assessed for compressive properties of human
neocartilage derived from Donor 1. (e) Young's modulus and (f) ultimate tensile strength (UTS) were assessed for tensile properties of human
neocartilage derived from Donor 1. All data presented as mean ± standard deviation. Groups with different letters indicate statistical difference
(p < 0.05). Ctrl: control; c‐ABC: chondroitinase‐ABC; LOX: lysyl oxidase‐like 2; TGF: transforming growth factor‐β1; CL: chondroitinase‐
ABC + lysyl oxidase‐like 2; TC: transforming growth factor‐β1 + chondroitinase‐ABC; TL: transforming growth factor‐β1 + lysyl oxidase‐like 2;
TCL: transforming growth factor‐β1 + chondroitinase‐ABC + lysyl oxidase‐like 2
288 KWON ET AL.the robustness of this treatment. Morphological difference of hAC
neocartilage derived from different donors is shown in Figure 4. The
effects of TCL treatment for Donors 2 and 3 were consistent with
those seen in Study I; the treatment increased thickness of
neocartilage and showed more intense histological staining (Figures 4
and S4). TCL treatment significantly increased GAG (increase by 170%
and 250% for Donors 2 and 3, respectively) and collagen contents
(increase by 80% and 120% for Donors 2 and 3, respectively) com-
pared with controls (Figure 5a,b). Both control and TCL‐treated
neocartilage were negative for type I collagen staining (Figure 6a).
Type II collagen staining was more intense in TCL‐treated neocartilage
when compared with control (Figure 6b).Mechanical properties, assessed in compression and tension, were
also evaluated. Similar to Donor 1, hAC neocartilage from Donors 2
and 3 was found to have an increased instantaneous modulus follow-
ing TCL treatment compared with controls (Figure 5c,d). Although, no
statistically significant difference was detected for the relaxation mod-
ulus of Donor 2's neocartilage after TCL treatment, an increase of 63%
was observed for Donor 3's neocartilage (Figure 5c,d). Similar to
neocartilage from Donor 1, the tensile stiffness and strength, follow-
ing TCL treatment, increased for both Donor 2 and Donor 3, when
compared with controls (Figure 5e,f). The effect was observed to be
greatest for Donor 3; the tensile stiffness and strength of Donor 2
neocartilage increased by 750% and 130%, respectively, whereas
FIGURE 4 Gross morphology and histology of self‐assembled human neocartilage at 5 and 8 weeks. (a) Top and side views of human
neocartilage derived from Donor 2 (left panel) and Donor 3 (right panel) at 5 and 8 weeks. (b) Hematoxylin and eosin (H&E) and Safranin O
(Saf‐O) staining of human neocartilage derived from Donor 2 (left panel) and Donor 3 (right panel) at 5 and 8 weeks. Ctrl: control; TCL:
transforming growth factor‐β1 + chondroitinase‐ABC + lysyl oxidase‐like 2 [Colour figure can be viewed at wileyonlinelibrary.com]
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respectively.3.2.2 | The effect of TCL treatment on hAC
neocartilage maturation
Study I investigated effects up to 5 weeks in culture. To investigate
TCL treatment's effect on neocartilage maturation, hAC neocartilage
from Donors 2 and 3 was evaluated at 5 and 8 weeks in this study.
After 8 weeks of culture, control neocartilage from both Donors 2
and 3 exhibited no apparent gross morphological difference, whereas
neocartilage treated withTCL had a more opaque appearance, possibly
due to cartilage matrix deposition (Figure 4). For all examined time
points, Safranin O, Picrosirius Red, and type II collagen staining were
more intense in TCL‐treated neocartilage versus controls (Figures 4,
S1, and 6b). Type I collagen production was not detected in either
control or TCL‐treated neocartilage (Figure 6a).
GAG content in control neocartilage from both donors remained
unchanged at 8 weeks when compared with 5 weeks (Figure 5). Inter-
estingly, GAG content following TCL treatment in Donor 3's
neocartilage further increased by 16% between 5 and 8 weeks
(Figure 5b). Collagen content in TCL‐treated neocartilage from both
donors significantly increased from 5 to 8 weeks by 27% (Figure 5a,
b). Compression and tensile properties of control neocartilage did
not change from 5 to 8 weeks (Figure 5). At all time points, mechanicalproperties of control neocartilage were inferior to those treated with
TCL. With TCL treatment, instantaneous modulus increased from 5
to 8 weeks by 40% and 53% for Donors 2 and 3, respectively
(Figure 5c,d). For all engineered human neocartilage examined here,
tensile stiffness and strength remained stable over 8 weeks of culture
(Figure 5e,f).4 | DISCUSSION
Although hACs represent a promising cell source for tissue‐engineered
cartilage products, the need for cell expansion results in loss of
chondrogenic potential and, ultimately, tissue‐engineered cartilage
lacking sufficient chondrogenic properties. Towards engineering func-
tional articular cartilage using human cells, this study sought to translate
the application of exogenous stimuli, TGF‐β1, c‐ABC, and LOXL2, to
generate mechanically robust tissue‐engineered neocartilage. In Study
I, it was hypothesized that treatment by TGF‐β1, c‐ABC, or LOXL2,
alone or in combination, would yield efficacy similar to those seen pre-
viously with animal cells when applied during self‐assembly of human
neocartilage. The results indicated that LOXL2 alone and a combined
treatment of TGF‐β1, c‐ABC, and LOXL2 (TCL) were efficacious as seen
with animal cells in enhancing the properties of hAC neocartilage. As
anticipated, the combined TCL treatment was most effective for
enriching GAG and collagen content and for improving compressive
FIGURE 5 Biochemical and mechanical properties of self‐assembled human neocartilage at 5 and 8 weeks. (a,b) Glycosaminoglycan (GAG) and
total collagen (COL) contents per wet weight (WW) in human neocartilage derived from Donors 2 and 3. (c,d) Instantaneous modulus and
relaxation modulus of human neocartilage derived from Donors 2 and 3. (e,f) Young's modulus and ultimate tensile strength (UTS) of human
neocartilage derived from Donors 2 and 3. All data presented as mean ± standard deviation. Groups with different letters indicate statistical
difference (p < 0.05)
FIGURE 6 Immunohistochemistry for types I and II collagen in self‐assembled human neocartilage derived from all donors. Shown is type I
collagen (a) and type II collagen (b) staining of human neocartilage derived from Donor 1 at 5 weeks and human neocartilage derived from
Donors 2 and 3 at 5 and 8 weeks. Nucleus pulposus and annulus fibrosus from human native intervertebral disc were used for positive and
negative controls. Ctrl: control; TCL: transforming growth factor‐β1 + chondroitinase‐ABC + lysyl oxidase‐like 2 [Colour figure can be viewed at
wileyonlinelibrary.com]
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TCL treatment synergistically increased tensile stiffness and strength
of human neocartilage. In Study II, it was hypothesized that the robust-
ness of TCL treatment on functional properties of human neocartilage
would be donor independent. Engineering neocartilage constructs using
expanded hACs derived from two additional donors, in the presence of
TCL treatment, exhibited improved biochemical andmechanical proper-
ties, supporting the hypothesis. Given that no data exist for the effect of
TCL treatment on hAC neocartilage maturation, it was further hypothe-
sized that TCL treatment would allow human neocartilage construct
properties to be retained or enhanced during neocartilage maturation.
TCL treatment, followed by a longer culture period, led to enhanced
compressive properties while maintaining tensile properties. Biochemi-
cally, GAG and total collagen content and type II collagen staining were
maintained or enhanced during the maturation phase. The results from
this study demonstrate, for the first time, that among the examined reg-
imens, a combination of TCL has the capacity to generate a rich cartilage
matrix and to increase tensile mechanical properties of human
neocartilage constructs derived from passaged hAC in a synergistic
manner. Further, hAC neocartilage properties were maintained or
enhanced during neocartilage maturation, regardless of donor source.
In Study I, the effects of c‐ABC on hAC‐derived self‐assembled
neocartilage were largely noncomparable with those seen with animal
cells (Bian et al., 2009; Natoli, Responte, et al., 2009; Natoli, Revell,
et al., 2009). Treatment of c‐ABC alone did not have a significant
impact on GAG and collagen content or on the compressive and ten-
sile mechanical properties (Figure 3). These results appear contradic-
tory to previous studies using bovine ACs, which demonstrated that
the temporary depletion of GAG by c‐ABC treatment increased colla-
gen content and enhanced tensile properties of tissue‐engineered car-
tilage (Bian et al., 2009; Natoli, Responte, et al., 2009; Natoli, Revell,
et al., 2009). Self‐assembled neocartilage derived from bovine ACs
demonstrated approximately 6% of GAG per wet weight at 2 weeks
and 10% at 4 weeks (Natoli, Revell, et al., 2009), whereas self‐
assembled hAC neocartilage in the present work contained only 2%
of GAG per wet weight even after 5 weeks of culture. Thus, given that
the matrix‐modifying role of c‐ABC in improving functional properties
is predicated on GAG depletion, there may not be sufficient GAG to
deplete in the hAC neocartilage at the treated time of t = 7 days,
resulting in no noticeable effects. However, it should be noted that
c‐ABC in conjunction with the other two stimuli resulted in beneficial
effects. Determining an appropriate time of c‐ABC application and cul-
ture duration will be necessary for c‐ABC to improve functional prop-
erties of hAC neocartilage.
In contrast to c‐ABC alone, LOXL2 treatment by itself had a sig-
nificant effect in enhancing tensile mechanical properties of hAC
neocartilage, consistent with a previous study performed with bovine
ACs (Makris, Responte, et al., 2014); tensile stiffness and strength
were increased by 25% and 100%, respectively, over controls. The
stimulatory effect of LOXL2 treatment by itself was further elevated
in the presence of TGF‐β1; this is a novel finding because a combined
treatment of TGF‐β1 with LOXL2 (TL) has not been previously exam-
ined. In this experiment, TL treatment significantly increased GAG and
collagen contents by 60% and 33%, respectively, when compared with
LOXL2 treatment only. A significant increase in tensile stiffness andstrength by 160% and 25%, respectively, was also shown when com-
paring TL‐treated against LOXL2‐treated groups. Compared with indi-
vidually applied TGF‐β1 and LOXL2, a combined treatment, TL,
synergistically increased tensile stiffness and strength by 230% and
150%, respectively, over controls, suggesting potential crosstalk
between the two stimuli to promote the functional properties of
hAC neocartilage. In short, TL treatment generated mechanically and
biochemically improved hAC neocartilage constructs due to their syn-
ergistic effect. The potential interactions between these two stimuli,
as uncovered here, may lead to other alternative ways to combine
them in enhancing neocartilage functional properties.
The combined treatment of the three stimuli, TGF‐β1, c‐ABC, and
LOXL2 on human neocartilage was the most beneficial in significantly
increasing the biochemical content and tensile properties. Previously,
this effect was only demonstrated for bovine fibrocartilage (Makris,
MacBarb, et al., 2014). In the previous study, TCL treatment exhibited
significantly enhanced collagen content and tensile mechanical prop-
erties of neofibrocartilage over untreated control, LOXL2 treatment
only, and TC treatment. Efficacy was shown to be resulting from a
combined benefit of increased collagen content by TGF‐β1, increased
fibril diameters by c‐ABC, and increased PYR crosslink content and
maturation by LOXL2 (Makris, MacBarb, et al., 2014). Consistently,
in the present study, the TCL combination yielded hAC neocartilage
with increased tensile stiffness and strength by 350% and 300%,
respectively, over controls; furthermore, these effects were synergistic
in nature. The improved chondrogenic functional properties demon-
strate successful translatability of the TCL treatment to human cells.
It is exciting to show that the synergistic response toTCL in Study
I was also demonstrated in other donors. In Study II, carrying forward
a combined TCL treatment, self‐assembled neocartilage constructs
derived from two additional donors were generated to evaluate the
robustness of TCL treatment in forming human neocartilage. Consis-
tent with outcomes derived from Donor 1, TCL treatment on hAC
neocartilage derived from Donors 2 and 3 significantly increased
GAG and collagen production, as well as type II collagen staining. Type
I collagen staining was not detected throughout the 8 weeks of culture
in either control or TCL‐treated neocartilage derived from all donors,
implying that type II collagen production in TCL‐treated neocartilage
was the major contributor to increased collagen content. These
encouraging results bode well for the assessment of additional donors
in future studies to fully assess donor variability.
Mechanically, both compressive and tensile properties were sig-
nificantly enhanced. Although TCL treatment was consistently effec-
tive for all donors, there were variations in the magnitude of the
effect. For example, TCL treatment was more efficacious in increasing
GAG content and in enhancing Young's modulus in neocartilage
derived from Donors 2 and 3 (170% and 250% increase for GAG;
750% and 850% increase for Young's modulus, respectively, over con-
trol) than Donor 1 (52% increase for GAG; 350% increase for Young's
modulus, over control). UTS by TCL treatment was increased in Donor
2's neocartilage by 130%, whereas neocartilage from Donors 1 and 3
both demonstrated 300% increases in UTS. It is possible that donor
variation with respect to age, race, and gender can result in differential
responses to the stimuli, leading to varied outcomes. Although the
mechanical properties of human native cartilage were not investigated
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large variability of mechanical properties of native tissue as a function
of location on the joint and depth. For example, compressive aggre-
gate modulus and tensile modulus of native articular cartilage vary
from 0.5 to 1.8 MPa and from 5 to 25 MPa, respectively (Akizuki et al.,
1986; Athanasiou, Agarwal, & Dzida, 1994; Athanasiou, Rosenwasser,
Buckwalter, Malinin, & Mow, 1991; Kempson, Freeman, & Swanson,
1968; Woo, Akeson, & Jemmott, 1976). Nevertheless, this work
shows that TCL treatment led to beneficial responses in hAC‐derived
neocartilage regardless of donor source, resulting in enriched bio-
chemical contents and enhanced mechanical properties.
Functional properties of bovine neocartilage were previously
shown to decline after 4 weeks of self‐assembly culture (Ofek et al.,
2008). Total collagen content was observed to decrease by 36%, and
the Young's modulus and UTS decreased by 92% and 71%, respec-
tively, from 4 to 8 weeks of culture. This observation signified the
need for exogenous stimuli to be applied after 4 weeks to enhance
functional properties (Ofek et al., 2008). In contrast to this previous
finding, the present study showed that human neocartilage maintained
GAG and total collagen contents and retained both compressive and
tensile properties (Figure 5). Aside from the difference in species, the
passage number is different; primary bovine juvenile chondrocytes
were used in this prior study (Ofek et al., 2008), whereas passage 3
hACs were used in this experiment. Importantly, because chondrocyte
expansion in monolayer immediately brings forth dedifferentiation
(Darling & Athanasiou, 2005), the hACs underwent an additional
aggregate suspension culture step that has been shown to promote
redifferentiation of expanded chondrocytes (Murphy et al., 2015;
Wolf et al., 2008). Specifically, the present study involved a treatment
consisting of culturing cell aggregates in TGF‐β1, GDF‐5, and BMP‐2,
which has been shown to lead hACs to express cartilage matrix
markers including SOX9, ACAN, and COL2A1, resulting in mechani-
cally robust neocartilage formation (Murphy et al., 2015). Thus, it is
plausible that aggregate culture was responsible for the maintenance
of hAC neocartilage properties during neocartilage formation and mat-
uration, not only by enhancing chondrogenic potentials of expanded
hACs but also by promoting the ability for hACs to retain their
chondrogenic phenotype in self‐assembly.
The beneficial effects of TCL treatment carried over 8 weeks of
self‐assembly culture. Excitingly, TCL treatment further enhanced
compressive properties by 40% and 53% for Donors 2 and 3, respec-
tively, without compromising tensile properties, in hAC neocartilage
cultured for 8 weeks when compared with 5 weeks. Whereas GAG
content was comparable or increased by 16% for Donors 2 and 3,
respectively, collagen content was both significantly increased by
27% from 5 to 8 weeks. In the present study, TGF‐β1 was continu-
ously employed throughout the culture period, contributing to an
increase in collagen content. Previously, it has been shown that a
gradual increase in collagen content during development of bovine
articular cartilage was associated with an increase in compressive
properties (Williamson, Chen, & Sah, 2001). Thus, the enhanced com-
pressive properties of hAC neocartilage at 8 weeks could be resulting
from the increased collagen content, indicative of neocartilage matu-
ration. Moreover, PYR crosslink concentration has been shown to
increase in bovine cartilage from fetus to adult, correlating withincreased tensile properties (Williamson, Chen, Masuda, Thonar, &
Sah, 2003). LOX‐mediated PYR collagen crosslinks in cartilage
explants grown in vitro have been shown to reach maturity after 7–
30 days (Ahsan, Harwood, McGowan, Amiel, & Sah, 2005). With
respect to engineered neotissue, neofibrocartilage treated with TCL
has been shown to have significantly increased PYR crosslink content
at 6 and 12 weeks, though no significant difference in the content
between these two time points was observed. It was suggested that
for neocartilage, longer time culture may be needed for formation of
mature PYR crosslinks to influence tensile properties (Makris,
MacBarb, et al., 2014). In the present work, although PYR crosslink
content in hAC neocartilage was not examined, it is plausible that in
light of the previous work with neofibrocartilage, a time point longer
than 8 weeks may be necessary to reach mature PYR crosslinks,
towards enhancing neocartilage tensile properties. Nevertheless, due
to its efficacy in neocartilage development, as well as maturation,
TCL treatment is emerging as a potent stimulation regimen in human
cartilage repair and regeneration.
The limited amount of hACs available from donor sites hampers
the use of autologous cells for tissue‐engineered products. The cell
number that can be obtained from cartilage can vary by donor,
and extensive expansion may be necessary if the initially available
cell number is low. Particularly, the self‐assembling process uses a
high initial seeding density of cells because it seeks to recapitulate
the developmental process of native cartilage formation. The self‐
assembling process is analogous to mesenchymal condensation in
which large numbers of cells in close proximity effect extensive
cell‐to‐cell interactions, resulting in extensive cartilage matrix forma-
tion. Because high numbers of cells are needed for the self‐
assembling process to initiate, it is essential that cells be expanded
in passage to achieve the high numbers needed. However, extensive
cell expansion can result in loss of their ability to redifferentiate and
fully revert into the chondrogenic phenotype (Schulze‐Tanzil et al.,
2002; Stokes et al., 2001). The gene expression of cartilage matrix
proteins (i.e., aggrecan and type II collagen) has been shown to
decrease as hAC passage number increased (Lin et al., 2008). More-
over, cell morphology and matrix components in tissue‐engineered
cartilage were largely affected by chondrocyte passage number
(Kang, Yoo, & Kim, 2007). These phenotypic changes call for a
new technique to effectively passage chondrocytes while maintain-
ing their chondrogenic phenotype. A recent study showed that
leporine ACs at passage 7, applied with postexpansion aggregate cul-
ture, generated self‐assembled neocartilage with properties similar to
or better than those derived from cells with lower passage numbers.
Because the present study used hACs at passage 3, it would be of
interest to examine whether the efficacy of aggregate culture,
shown in the leporine model, can be applicable to hACs. Further,
applying TCL to neocartilage formed from hACs of higher passage
numbers should be examined to see if similar improvements can be
obtained. In addition, because many growth factors are involved,
clinical use of the engineered neocartilage would require determina-
tion of the residual levels of growth factors in the final product used
for cartilage repair (U.S. Food & Drug Administration, 2008). Such
studies will be valuable towards further enhancing the translational
use of autologous cells for cartilage repair and restoration.
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The lack of sufficient functional properties of neocartilage derived
from expanded hACs presents challenges towards clinical use. This
study showed that exogenous stimuli TGF‐β1, c‐ABC, and LOXL2
enhanced the functional properties of neocartilage, derived from
expanded hACs. When the three stimuli were combined, tensile stiff-
ness and strength in human neocartilage were synergistically
increased by 350% and 300%, respectively, over controls. The influ-
ence of TCL treatment was evaluated using two additional donors.
For all donors, tensile stiffness and strength were increased by up to
850% and 300%, respectively, with TCL treatment. Treatment effects
persisted in long‐term culture, even after cessation of certain stimuli
(of the three stimuli, only TGF‐β1 was applied continuously). Com-
pressive properties and total collagen content were further improved
between 5 and 8 weeks without compromising tensile properties or
GAG content. This suggests that TCL treatment improves mechanical
maturation of constructs and long‐term stability of cartilage matrix
synthesis. Inasmuch as neocartilage treated with TCL exhibits robust
functional properties and maturation, it is recommended that TCL
treatment be considered as a new, effective strategy for tissue‐
engineering human neocartilage.
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Figure S1. Picrosirius red staining in self‐assembled human
neocartilage. Shown is the staining of (A) human neocartilage derived
from Donor 1 at 5 weeks and (B) human neocartilage derived from
Donor 2 and 3 at 5 and 8 weeks.
Figure S2. Cross‐sectional images of the entire self‐assembled human
neocartilage. Shown is the H&E staining of (A) human neocartilage
derived from Donor 1 at 5 weeks and (B) human neocartilage derived
from Donor 2 and 3 at 5 and 8 weeks.
Figure S3. H&E staining of self‐assembled human neocartilage (scale‐
up of Figure 2B; Donor 1 at 5 weeks).
Figure S4. H&E staining of self‐assembled human neocartilage (scale‐
up of Figure 4B; Donor 2 and 3 at 5 and 8 weeks).
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